版本:
中国

BRIEF-Servier,CTI Biopharma expand Pixuvri license and collaboration agreement

April 25 Cti Biopharma Corp

* Servier and CTI Biopharma expand license and collaboration agreement to develop and commercialize Pixuvri

* Says Servier will commercialize Pixuvri in all markets except US

* Says CTI Biopharma will retain rights to commercialize Pixuvri in US

* CTI Biopharma - Servier to pay CO EUR 12 million with potential for CO to receive EUR 76 million in additional sales and regulatory milestone payments

* CTI Biopharma - as specific post-authorization requirement, Pixuvri is currently being investigated in a phase iii clinical trial, pix306

* CTI Biopharma - Pixuvri granted conditional marketing authorization from European Commission Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐